恒瑞医药(600276.SH)：HR091506片上市许可申请获国家药监局受理

Core Viewpoint - Heng Rui Medicine has received acceptance notification from the National Medical Products Administration for its HR091506 tablet, aimed at long-term treatment of hyperuricemia in gout patients [1] Group 1: Product Development - HR091506 is a self-developed oral sustained-release tablet utilizing gastric retention technology, featuring pulse release characteristics [1] - The product consists of a rapid-release part and a delayed-release part, designed to quickly achieve effective blood drug concentration and maintain it over an extended period [1] - The cumulative R&D investment for HR091506 has reached approximately 126.7 million yuan (unaudited) [1]